Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 14Gastrointestinal 9Other 4Lymphoid 4Genitourinary 4Other hematologic neoplasm 3Tumor-Agnostic 2Thoracic 2Plasma cell 2Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1CNS 1

Conditions

Skin Neoplasms 1Motor Activity 1Melanoma 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 70Nivolumab 47Ipilimumab 27Specimen Handling 15Magnetic Resonance Spectroscopy 15trametinib 14Biopsy 13dabrafenib 11cemiplimab 11avelumab 11Cyclophosphamide 11binimetinib 10Radiotherapy 9CTLA-4 Antigen 9fludarabine 8encorafenib 7atezolizumab 7Radiosurgery 7Immunoglobulin G 7Disulfides 7Cisplatin 7fludarabine phosphate 6durvalumab 6tislelizumab 5relatlimab 5lenvatinib 5dostarlimab 5Pemetrexed 5Paclitaxel 5Introns 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Exercise × Dermatologic × Clear all
NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡